Filtered By:
Specialty: Neurology
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 127 results found since Jan 2013.

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants
ConclusionsIn this expert opinion paper, it is suggested that IVT can be performed in patients selected according to the time elapsed since the drug was last taken, renal function, type of hospital where the patient is admitted and plasma concentration of DOAC.
Source: European Journal of Neurology - March 9, 2018 Category: Neurology Authors: E. Touz é, Y. Gruel, I. Gouin‐Thibault, E. De Maistre, S. Susen, P. Sie, L. Derex Tags: Original Article Source Type: research

Encouraging Early Safety Data for Dabigatran in Stroke Encouraging Early Safety Data for Dabigatran in Stroke
Results of a preliminary study show no increase in symptomatic hemorrhagic transformation with dabigatran vs aspirin in patients with TIA or minor stroke.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - May 30, 2018 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6  mg/kg of recombinant tissue-type plasminogen activator. Case reports
In the last decade, the novel oral anticoagulant (NOAC) dabigatran (a direct thrombin inhibitor), rivaroxaban, apixaban and edoxaban (direct factor Xa inhibitors) have been approved for primary and secondary prevention of stroke in patients with atrial fibrillation (AF) [1]. Compared with vitamin k antagonists such as warfarin, the NOACs offer benefits in terms of efficacy, safety and convenience [2]. The only currently approved treatment for acute stroke with a class I recommendation and level A evidence is intravenous recombinant tissue-type plasminogen activator alteplase (IV rt-PA) [4].
Source: Journal of the Neurological Sciences - July 7, 2018 Category: Neurology Authors: Massimiliano Plastino, Domenico Bosco, Laura Giofr è, Dario Cristiano, Franco Galati, Paolo Postorino, Arturo Consoli, Antonietta Fava, Domenico Consoli Tags: Letter to the Editor Source Type: research

Idarucizumab-facilitated intravenous thrombolysis in acute ischemic stroke: A therapeutic strategy requiring further investigation
Although dabigatran does a better job reducing the risk of cardioembolic stroke than warfarin in patients with non-valvular atrial fibrillation, 0.92 –1.34% of dabigatran users still develop isch emic stroke [1]. The usage of warfarin (even at a suboptimal therapeutic level) increases the risk of hemorrhagic transformation (HT) after intravenous thrombolysis (IT) [2]; therefore, current guidelines advise against performing IT in patients receiv ing any direct oral anti-coagulant (DOAC), including dabigatran [3].
Source: Journal of the Neurological Sciences - September 13, 2018 Category: Neurology Authors: Hsiao Yu-Jen, Tsai Yi-Te, Li-Kai Tsai, Fang Chen-wen Tags: Letter to the Editor Source Type: research

Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants.
CONCLUSIONS: Little is known about ischemic strokes under NOAC. To increase the knowledge, the data of 469 ischemic strokes which occurred in NOAC-investigating trials should be analyzed. Furthermore ischemic and bleeding events under NOAC outside clinical trials should be reported. An international registry, independent from the pharmaceutical industry for collecting these informations is desirable. PMID: 24821640 [PubMed - as supplied by publisher]
Source: Neurologia i Neurochirurgia Polska - March 1, 2014 Category: Neurology Authors: Stöllberger C, Finsterer J Tags: Neurol Neurochir Pol Source Type: research

Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin Clinical Sciences
Conclusions— In this sample of AF patients with ICB on oral anticoagulants, dabigatran was not associated with higher in-hospital mortality compared with warfarin. Hence, reluctance to use dabigatran because of a lack of approved reversal agents is not supported by our results.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Alonso, A., Bengtson, L. G. S., MacLehose, R. F., Lutsey, P. L., Chen, L. Y., Lakshminarayan, K. Tags: Cerebrovascular disease/stroke, Coumarins, Other anticoagulants, Arrhythmias, clinical electrophysiology, drugs, Anticoagulants Clinical Sciences Source Type: research

Recurrent Ischemic Stroke in a Patient with the Trousseau Syndrome Treated with Dabigatran
Source: Journal of Stroke and Cerebrovascular Diseases - February 19, 2014 Category: Neurology Authors: Kosuke Yoshida, Takashi Kimura, Yoko Aburakawa, Yasuhiro Suzuki, Kenji Kuroda, Osamu Yahara Tags: Case Reports Source Type: research

Proposed Approach to Thrombolysis in Dabigatran-Treated Patients Presenting with Ischemic Stroke
Source: Journal of Stroke and Cerebrovascular Diseases - January 9, 2014 Category: Neurology Authors: Mahesh Kate, Artur Szkotak, Adam Witt, Ashfaq Shuaib, Kenneth Butcher Tags: Original Articles Source Type: research

Cardioembolic stroke in a patient taking Dabigatran Etexilate: The first case report of clinical and pharmacologic resistance
Dabigatran Etexilate (DE) was the first oral direct thrombin inhibitor approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) [1,2]. One of its main advantages relies on predictable pharmacokinetics allowing a fixed dosage for each patient. In fact, although a range of pharmacokinetic response to DE has been demonstrated, up until now no case has been described of clinical and pharmacologic resistance.
Source: Journal of the Neurological Sciences - August 29, 2014 Category: Neurology Authors: João Sargento-Freitas, Fernando Silva, João Pego, Cristina Duque, Gustavo Cordeiro, Luís Cunha Tags: Letter to the Editor Source Type: research

Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients
ConclusionsWe report the largest series of cerebral vein thrombosis patients treated with dabigatran. Clinical outcome was excellent in most patients and not different from other studies. Dabigatran could possibly be considered an alternative to warfarin; nevertheless, further prospective assessment with randomized controlled studies is warranted.
Source: International Journal of Stroke - February 1, 2015 Category: Neurology Authors: Marcelo D. Mendonça, Raquel Barbosa, Vera Cruz‐e‐Silva, Sofia Calado, Miguel Viana‐Baptista Tags: Research Source Type: research

Letter by Feng et al Regarding Article, "Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control" Letters to the Editor
Source: Stroke - February 23, 2015 Category: Neurology Authors: Feng, X., Huan, Y., Lv, Y. Tags: Secondary prevention, Acute Cerebral Infarction Letters to the Editor Source Type: research

Response to Letter Regarding Article, "Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control" Letters to the Editor
Source: Stroke - February 23, 2015 Category: Neurology Authors: Chan, P.-H., Hai, J. J., Siu, C.-W. Tags: Coumarins Letters to the Editor Source Type: research

Intravenous thrombolysis in wake‐up stroke in a 92‐year‐old patient under dabigatran
Source: International Journal of Stroke - September 24, 2015 Category: Neurology Authors: Alessio Pieroni, Maria Luisa Capuana, Anne Falcou, Danilo Toni Tags: Letter to the editor Source Type: research

Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke
We report the case of a 76-year-old woman, who received intravenous thrombolysis for acute treatment of an ischemic stroke immediately after elimination of dabigatran by intravenous application of the monoclonal antibody fragment, idarucizumab, which specifically reverses dabigatran anticoagulation. Currently, the RE-VERSE AD clinical trial is testing idarucizumab in two indications, uncontrolled bleeding and the need for urgent interventions or surgery.
Source: Journal of the Neurological Sciences - September 7, 2016 Category: Neurology Authors: Joachim G. Schulz, Bernard Kreps Tags: Letter to the Editor Source Type: research

Successful Treatment with t-PA of a Stroke Patient after Reversal of Dabigatran with Idarucizumab (P3.291)
Conclusions:We report the first successful treatment with t-PA of an acute stroke patient after reversal of dabigatran with idarucizumab.Disclosure: Dr. Cossey has nothing to disclose. Dr. Reddy has nothing to disclose. Dr. Savitz has received research support from the NIH. Dr. Grotta has received personal compensation for activities with Frazer and Stryker. Dr. Grotta has received research support from Genentech and Medtronic.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cossey, T., Reddy, S., Savitz, S., Grotta, J. Tags: Cerebrovascular Disease Case Reports II Source Type: research